A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors

Detalhes bibliográficos
Principais autores: Pacey, S, Blackhall, F, Garcia-Corbacho, J, Lipplaa, A, Fusi, A, Kumar, S, Hategan, M, Derham, J, Laviste, G, Halford, S, Foxton, C, McLeod, R, Wan, S, Talbot, D
Formato: Conference item
Publicado em: Oxford University Press 2016

Registros relacionados